Overview

Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis

Status:
Recruiting

Trial end date:
2022-11-01

Target enrollment:

Participant gender:

Summary

This study is designed to evaluate efficacy, safety, pharmacokinetics (PK) and immunogenicity of subcutaneously administered DMB-3115 in comparison with Stelara for treatment of moderate to severe chronic plaque psoriasis.

Phase:

Phase 3

Details

Lead Sponsor:

Dong-A ST Co., Ltd.

Collaborator:

Meiji Seika Pharma Co., Ltd.

Treatments:

Ustekinumab